5th Annual Partnerships in Clinical Trials Congress (PCT) and Exhibition

Posted:
15
August 2006

Win a VIP invite to the Partnerships in Clinical Trials congress (PCT), Belgium including:

  • Delegate pass for the duration of the event
  • Travel and accommodation costs

Richmond Pharmacology will be exhibiting at this years PCT congress 13th-15th November 2006, Brussels Expo, Belgium www.ct-partnerships.com.Managing Director Dr Jorg Taubel of Richmond Pharmacology is on the panel of guest speakers and will be covering the topic:'Effective Partnering between Sponsors & Niche Providers'Examining:

  • What niche providers can deliver that global CROs cannot
  • How do partnerships between smaller sponsors & niche providers benefit both
  • The role niche providers play in global clinical trials

If you are planning to attend the conference then please take a look at our prize draw below:We are running a prize draw to win a VIP invite to the PCT event which includes:

  • Delegate pass for 2 days for 1 guest
  • Travel and accommodation costs for the duration of the event for 1 guest

To attend the conference as a guest of Richmond Pharmacology why not enter the prize draw below to be in with a chance to win.To enter, click here

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more